Teclistamab serves as a revolutionary novel anti-BCMA antibody drug compound, designated JNJ-64007957, featuring immense promise in the management of multiple myeloma. This innovative agent operates by specifically targeting Teclistamab laboratory grade sample BCMA, a marker highly present on the surface of myeloma cells. Through this specific mech